Spruce Biosciences Builds Its Commercial War Chest for a Rare Disease Bet

SOUTH SAN FRANCISCO, CA – June 15, 2026 – In the high-stakes world of biotechnology, personnel announcements often serve as strategic tells, revealing a company’s hand long before the cards are played. For Spruce Biosciences (Nasdaq: SPRB), today’s appointment of two seasoned executives is more than a routine update; it is a clear and decisive signal that the company is transitioning from a clinical-stage developer into a commercial-ready organization, placing a major bet on its lead candidate for a devastating pediatric disorder.

The company announced the hiring of Eric Jordan as Vice President, Marketing, and Tina Gullotta as Vice President, Finance and Corporate Controller. These are not junior additions but proven leaders brought in to construct the commercial and financial infrastructure needed to launch what could be the first-ever approved therapy for Sanfilippo Syndrome Type B. The move telegraphs confidence and a disciplined approach to navigating the final, most treacherous leg of the drug development journey: bringing a product to market.

Assembling the Launch Playbook

For a company like Spruce, whose future hinges on the success of its lead candidate, tralesinidase alfa enzyme replacement therapy (TA-ERT), getting the commercial launch right is everything. This is where the recruitment of Eric Jordan becomes a masterstroke. With over 20 years in pharmaceutical and biotech marketing, Jordan brings a playbook written from deep experience in rare disease launches—a specialized field where success is measured not by mass-market appeal but by precision execution.

His track record is a map of past victories. Most notably, during his tenure as Vice President of Marketing at Dompé Pharmaceuticals, he spearheaded the U.S. launch of Oxervate, a treatment for a rare eye disease, and grew it into a $1 billion brand. This achievement is the gold standard for rare disease commercialization, demonstrating an ability to navigate complex reimbursement landscapes, build physician awareness from scratch, and connect with a small but desperate patient population. His more recent experience at BridgeBio, leading launch planning for another rare endocrine disorder therapy, further sharpens his relevant expertise. This is not just experience; it is a specific, high-value skill set that directly de-risks Spruce’s impending launch.

“Spruce is on the cusp of delivering what could be the first disease-modifying treatment option for patients with Sanfilippo Syndrome Type B, and the opportunity to help launch a therapy with this kind of potential impact is exactly what drew me to the team,” Mr. Jordan said in the company’s statement. His focus is clear: to “build the marketing foundation needed to bring TA-ERT to the patients and families who have been waiting for it.”

Fortifying the Financial Foundation

If Jordan is building the engine to drive revenue, Tina Gullotta is reinforcing the chassis to handle the stress of the journey. A 25-year veteran of life sciences finance and a Certified Public Accountant, Gullotta’s appointment is a testament to the discipline required to transition from a cash-burning R&D firm to a publicly traded commercial entity. Her experience is a checklist of the critical functions needed for this phase: SEC reporting, Sarbanes-Oxley (SOX) compliance, and capital markets fundraising.

Her previous roles at Sunesis Pharmaceuticals and Frontier Medicines Corporation saw her guiding organizations through clinical growth and operational transformation. This background is vital for Spruce, which, despite a soaring stock price that has surged over 800% in the past year, faces the financial realities of its transition. A 10-Q filing from May 2025 noted that existing cash would not be sufficient to fund operations for the next twelve months, raising substantial doubt about its ability to continue as a going concern without additional financing. Gullotta’s appointment is a direct and strategic answer to that challenge. Her expertise in managing public company finances and supporting fundraising activities is precisely what Spruce needs to secure its financial footing ahead of a costly product launch.

“I am thrilled to join Spruce at such a pivotal moment in the company’s evolution,” Ms. Gullotta stated. “I look forward to partnering with the leadership team to scale the finance and accounting organization, strengthen our controls and reporting infrastructure, and support Spruce’s transition to a commercial-stage company.”

A Beacon of Hope for a Devastating Disease

The strategic hires are in service of a singular, profound goal: delivering TA-ERT to patients. Sanfilippo Syndrome Type B (MPS IIIB) is an ultra-rare and universally fatal genetic disorder often described as a “childhood Alzheimer’s.” Children with the disease lack a critical enzyme, leading to the toxic buildup of heparan sulfate in the brain. This causes catastrophic neurodegeneration, stripping them of their ability to speak, walk, and recognize their families before leading to an early death, typically in their teenage years. There are no FDA-approved therapies.

Spruce’s TA-ERT is designed to overcome the primary obstacle that has thwarted past efforts: the blood-brain barrier. Administered directly into the cerebrospinal fluid, the therapy has shown remarkable promise. In long-term clinical data presented this month, TA-ERT demonstrated a rapid and sustained reduction of the toxic heparan sulfate. More importantly for patients and families, it showed a stabilization of cognitive function, communication, and motor skills over six years when compared to the disease’s natural, tragic progression. This data underpins the therapy's multiple FDA designations, including Breakthrough Therapy and Fast Track, which are reserved for drugs showing substantial potential improvement over available care for serious conditions.

The company plans to submit its Biologics License Application (BLA) in the first quarter of 2026, seeking accelerated approval based on a surrogate endpoint agreed upon with the FDA. The appointments of Jordan and Gullotta are perfectly timed to prepare for this milestone, ensuring that if and when the FDA gives its blessing, the company is ready to execute from day one.

Ultimately, the story of Spruce Biosciences is a case study in building a winner. The foundation is the science—the promising data behind TA-ERT. But in the unforgiving landscape of biotech, science alone is not enough. The appointments of Eric Jordan and Tina Gullotta represent the construction of a resilient operational structure upon that foundation. They are importing proven playbooks for commercial execution and financial discipline, two pillars of permanence that transform a promising therapy into a sustainable enterprise. As CEO Javier Szwarcberg noted, their expertise is “critical to operating as a commercial-stage organization.” For investors and, more importantly, for the families hoping for a breakthrough, these hires are the clearest sign yet that Spruce is not just planning to compete; it is building to win.